Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methanesulfonyl fluoride (MSF) is a small molecule and potent, irreversible inhibitor of acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the nervous system. By inhibiting this enzyme, MSF increases levels of acetylcholine, which can affect neurotransmission in both central and peripheral nervous systems. It has been investigated as an experimental drug for potential use in treating Alzheimer's disease due to its ability to modulate cholinergic signaling. Methanesulfonyl fluoride is highly toxic and corrosive, with significant safety hazards upon inhalation or contact with moisture; it produces toxic fumes including hydrogen fluoride and sulfur oxides when decomposed or exposed to water[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methanesulfonyl fluoride.